Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Sally Massey, the Chief Human Resources Officer at Colgate-Palmolive Co. (NYSE:CL), executed a significant stock sale recently. According to a filing with the Securities and Exchange Commission, Massey sold 8,000 shares of common stock on February 25, 2025. The shares were sold at a weighted average price of $92.019 per share, totaling approximately $736,152. The transaction comes as the $73 billion consumer goods giant maintains strong financial health, with impressive gross profit margins of 60.6% and a 35-year track record of consecutive dividend increases, according to InvestingPro data.
Following the transaction, Massey retains direct ownership of 14,805 shares. Additionally, she holds an indirect interest of 7,865 shares through the issuer’s 401(k) plan trustee. The sale was conducted as part of routine financial management, with shares sold at prices ranging from $92.01 to $92.02. The stock currently trades near its Fair Value, with InvestingPro analysis revealing 10+ additional insights and a comprehensive research report available for deeper analysis of Colgate-Palmolive’s financial outlook.
In other recent news, Colgate-Palmolive Company has announced its agreement to acquire Care TopCo Pty Ltd, the owner of the Australian pet food brand Prime100. This strategic acquisition aims to expand Colgate’s Hill’s Pet Nutrition division into the fresh pet food category, enhancing its presence in the Australian market. The acquisition is expected to close in the second quarter of 2025, pending regulatory approval.
Meanwhile, TD Cowen has maintained a Buy rating on Colgate-Palmolive, setting a price target of $100. This follows the company’s fourth-quarter gross margin expansion, although slower than in previous quarters due to foreign exchange effects. In contrast, Stifel has adjusted its price target for Colgate-Palmolive to $93 from $95, maintaining a Hold rating. Stifel noted mixed financial results for the fourth quarter and projected organic sales growth challenges in the first half of 2025.
Barclays (LON:BARC) reiterated an Equalweight rating with an $83 target, emphasizing Colgate’s significant sales in emerging markets and the challenges posed by diminishing inflationary pricing and currency headwinds. Lastly, Raymond (NSE:RYMD) James reduced its price target to $105 from $110 while maintaining an Outperform rating, citing Colgate-Palmolive’s flexible operating structure and strong market shares as positive long-term factors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.